News articles about Horizon Therapeutics (NASDAQ:HPTX) have trended somewhat positive recently, according to Accern Sentiment. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Horizon Therapeutics earned a news impact score of 0.23 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 45.8748081707112 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
Horizon Therapeutics (HPTX) remained flat at $$45.99 during trading hours on Friday. Horizon Therapeutics has a one year low of $20.23 and a one year high of $46.96. The stock has a market capitalization of $964.29 and a PE ratio of -1,533.00.
ILLEGAL ACTIVITY NOTICE: “Horizon Therapeutics (HPTX) Given Media Impact Rating of 0.23” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/13/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-horizon-therapeutics-hptx-share-price.html.
Horizon Therapeutics Company Profile
Horizon Therapeutics, Inc, formerly Hyperion Therapeutics, Inc, is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder.
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.